Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Immunologic Research
Erschienen in: Immunologic Research 6/2020

01.10.2020 | COVID-19 | Review Zur Zeit gratis

Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development

verfasst von: Daniela Calina, Chandan Sarkar, Andreea Letitia Arsene, Bahare Salehi, Anca Oana Docea, Milon Mondal, Muhammad Torequl Islam, Alireza Zali, Javad Sharifi-Rad

Erschienen in: Immunologic Research | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

During the COVID-19 pandemic in a modern era, there is a global consensus on the need for the rapid development of a vaccine against SARS-CoV-2 for effective and sustainable control. Developing these vaccines is fundamental to public health. This urgent need is supported by the scientific explosion in structural and genomic biology that facilitates the urgent development of an ideal COVID-19 vaccine, using new pathways to facilitate its large-scale development, testing, and manufacture. Here, we summarize the types of COVID-19 candidate vaccines, their current stage in early testing in human clinical trials, and the challenges for their implementation.
Literatur
1.
Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M, et al. A new threat from an old enemy: re-emergence of coronavirus. Int J Mol Med. 2020;45(6):1631–43.PubMedPubMedCentral
2.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.PubMedPubMedCentral
3.
Goumenou M, Sarigiannis D, Tsatsakis A, Anesti O, Docea AO, Petrakis D, et al. COVID-19 in Northern Italy: an integrative overview of factors possibly influencing the sharp increase of the outbreak. Mol Med Rep. 2020;22(1):20–32.PubMedPubMedCentral
4.
Tsatsakis A, Petrakis D, Nikolouzakis TK, Docea AO, Calina D, Vinceti M, et al. COVID-19, an opportunity to reevaluate the correlation between long-term effects of anthropogenic pollutants on viral epidemic/pandemic events and prevalence. Food Chem Toxicol. 2020;141:111418.PubMedPubMedCentral
5.
6.
Hsueh P-R, Huang LM, Chen PJ, Kao CL, Yang PC. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004;10(12):1062–6.PubMed
7.
Beavis KG, Matushek SM, Abeleda APF, Bethel C, Hunt C, Gillen S, et al. Evaluation of the EUROIMMUN anti-SARS-CoV-2 ELISA assay for detection of IgA and IgG antibodies. J Clin Virol. 2020;129:104468.PubMedPubMedCentral
8.
Ayouba A, Thaurignac G, Morquin D, Tuaillon E, Raulino R, Nkuba A, et al. Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. J Clin Virol. 2020;129:104521.PubMedPubMedCentral
9.
10.
Wang C, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):1–6.
11.
12.
Tsang JS, Dobaño C, VanDamme P, Moncunill G, Marchant A, Othman RB, et al. Improving vaccine-induced immunity: can Baseline Predict Outcome? Trends Immunol. 2020;41:457–65.PubMedPubMedCentral
13.
14.
Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969–73.PubMed
15.
Yaqinuddin A. Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities. Med Hypotheses. 2020;144:110049.PubMedPubMedCentral
16.
17.
18.
Calina D, Docea A, Petrakis D, Egorov A, Ishmukhametov A, Gabibov A, et al. Towards effective COVID-19 vaccines: updates, perspectives and challenges. Int J Mol Med. 2020;46(1):3–16.PubMedPubMedCentral
19.
20.
Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368(6493):860–8.PubMed
21.
22.
Calina D, Docea A, Petrakis D, Egorov A, Ishmukhametov A, Gabibov A, et al. Towards effective COVID-19 vaccines: updates, perspectives and challenges (Review). Int J Mol Med. 2020;46(1):3–16.PubMedPubMedCentral
23.
McAnulty JM, et al. Vaccine failures and vaccine effectiveness in children during measles outbreaks in New South Wales, March-May 2006. Commun Dis Intell Q Rep. 2009;33(1):21.PubMed
24.
Haralambieva IH, Ovsyannikova IG, Pankratz VS, Kennedy RB, Jacobson RM, Poland GA. The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Rev Vaccines. 2013;12(1):57–70.PubMedPubMedCentral
25.
Kudrat-E-Zahan M, et al. A perspective on emerging therapeutic interventions for COVID-19.
26.
Wiedermann U, Garner-Spitzer E, Wagner A. Primary vaccine failure to routine vaccines: why and what to do? Hum Vaccin Immunother. 2016;12(1):239–43.PubMedPubMedCentral
27.
Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36–44.PubMed
28.
29.
Peeples L. News feature: avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proc Natl Acad Sci. 2020;117(15):8218–21.PubMedPubMedCentral
30.
Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008;197(7):950–6.PubMed
31.
National Academies of Sciences, E. and Medicine, Integrating clinical research into epidemic response: the Ebola experience. National Academies Press; 2017.
32.
Zhu F-C, Wurie AH, Hou LH, Liang Q, Li YH, Russell JBW, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017;389(10069):621–8.PubMed
33.
Callow KA, Parry HF, Sergeant M, Tyrrell DAJ. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105(2):435–46.PubMedPubMedCentral
34.
Cao W-C, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357(11):1162–3.PubMed
35.
Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562–4.PubMedPubMedCentral
36.
Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, al Nsour M, et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22(10):1824–6.PubMedPubMedCentral
37.
38.
Alshukairi AN, et al. Antibody response and disease severity in healthcare worker MERS survivors. Emerg Infect Dis. 2016;22(6):1113–5.PubMedCentral
39.
Organization, W.H., DRAFT landscape of COVID-19 candidate vaccines. World. 2020.
40.
Marston HD, Paules CI, Fauci AS. The critical role of biomedical research in pandemic preparedness. JAMA. 2017;318(18):1757–8.PubMed
41.
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79.PubMedPubMedCentral
42.
Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963.PubMedPubMedCentral
43.
Bliss CM, Bowyer G, Anagnostou NA, Havelock T, Snudden CM, Davies H, et al. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Sci Rep. 2018;8(1):3390.PubMedPubMedCentral
44.
Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med. 2016;374(17):1635–46.PubMed
45.
Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020;580(7805):576–7.PubMed
46.
Yang L, Tian D, Liu W. Strategies for vaccine development of COVID-19. Sheng Wu Gong Cheng Xue Bao. 2020;36(4):593.PubMed
47.
48.
Petricciani J, Sheets R, Griffiths E, Knezevic I. Adventitious agents in viral vaccines: lessons learned from 4 case studies. Biologicals. 2014;42(5):223–36.PubMed
49.
Agency, E.M., Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials. 2020.
50.
De Mattia F, et al. The consistency approach for quality control of vaccines–a strategy to improve quality control and implement 3Rs. Biologicals. 2011;39(1):59–65.PubMed
51.
Powlson J, et al. Characterization of antigenic MHC-class-I-restricted t cell epitopes in the glycoprotein of ebolavirus. Cell Rep. 2019;29(9):2537–2545.e3.PubMedPubMedCentral
52.
Daneshian M, Busquet F, Hartung T, Leist M. Animal use for science in Europe. Alternatives to animal experimentation. ALTEX. 2015;32(4):261–74.PubMed
53.
Pronker ES, Weenen TC, Commandeur H, Claassen EHJHM, Osterhaus ADME. Risk in vaccine research and development quantified. PLoS One. 2013;8(3):e57755.PubMedPubMedCentral
54.
Struck M-M. Vaccine R&D success rates and development times. Nat Biotechnol. 1996;14(5):591–3.PubMed
55.
FDA, Investigational new drug (IND) Application. 2020.
56.
Agency, E.M., Clinical Trial Regulation. 2019.
57.
Bulik NB, et al. Reactogenicity and medically attended adverse events following hexavalent vaccination: an observational prospective study. Farmacia. 2019;67(6):1018–24.
58.
Bucsa C, et al. Adverse events following measles-mumps-rubella vaccination. A prospective observational study. Farmacia. 2020;68(2):219–24.
59.
60.
Le TT, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–6.
61.
Medicine, N.L.o., Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis SARS CoV-2 infection (COVID-19). 2020.
62.
Medicine, N.L.o., Safety, tolerability and immunogenicity of INO-4800 for COVID-19 in healthy volunteers. 2020.
63.
Medicine, N.L.o., Phase I clinical trial of a COVID-19 vaccine in 18-60 healthy adults (CTCOVID-19). 2020.
64.
Medicine, N.L.o., Immunity and safety of Covid-19 synthetic minigene vaccine. 2020.
65.
Arsene AL, et al. A new era for the therapeutic management of the ongoing COVID-19 pandemic. Farmacia. 2020;68(2):185–96.
Metadaten
Titel
Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development
verfasst von
Daniela Calina
Chandan Sarkar
Andreea Letitia Arsene
Bahare Salehi
Anca Oana Docea
Milon Mondal
Muhammad Torequl Islam
Alireza Zali
Javad Sharifi-Rad
Publikationsdatum
01.10.2020
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 6/2020
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-020-09154-4

Weitere Artikel der Ausgabe 6/2020

Immunologic Research 6/2020 Zur Ausgabe

Original Article

Rectal cancer induces a regulatory lymphocytic phenotype in the tumor-draining lymph nodes to promote cancer cell installation

Original Article

Effects of whole-body cryotherapy on the innate and adaptive immune response in cyclists and runners

Original Article

Patients with pemphigus are at an increased risk of developing rheumatoid arthritis: a large-scale cohort study

Original Article

PROMIS-29 survey confirms major impact of fatigue on health-related quality of life in common variable immunodeficiency

Original Article

The relationships of serum homocysteine levels and traditional lipid indicators with disease activity and coronary artery involvement in Takayasu arteritis

Original Article

Immune characteristics distinguish patients with severe disease associated with SARS-CoV-2

Passend zum Thema

ANZEIGE

IPD-Fallzahlen & Pneumokokken-Impfung bei Kindern in Deutschland

Das Niveau der postpandemischen Fallzahlen für invasive Pneumokokken-Erkrankungen (IPD) ist aus Sicht des Referenz-Zentrums für Streptokokken in Aachen alarmierend [1]. Wie sich die monatlichen IPD-Fallzahlen bei Kindern und Jugendlichen von Juli 2015 bis März 2023 entwickelt haben, lesen Sie hier.

ANZEIGE

HPV-Impfung: Auch für junge Erwachsene sinnvoll und wichtig

Auch nach dem 18. Lebensjahr kann eine HPV-Impfung sinnvoll und wichtig sein. Viele gesetzliche Krankenkassen übernehmen die Kosten auch zu einem späteren Zeitpunkt noch.

ANZEIGE

Impfstoffe – Krankheiten vorbeugen, bevor sie entstehen

Seit mehr als 130 Jahren entwickelt und produziert MSD Impfstoffe für alle Altersgruppen. Hier finden Sie nützliche Informationen und Praxismaterialien rund um das Thema Impfen.

MSD Sharp & Dohme GmbH
Bildnachweise